Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGOBSERVATIONAL

Pathogenicity of Species of the Achromobacter Genus in Patients From Reunion Island With Cystic Fibrosis

Pathogenicity of Species of the Achromobacter Genus in Patients With Cystic Fibrosis: a Prospective Multicentre Exploratory Study of a Cohort in Réunion Island.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The pathogenicity of Achromobacter bacteria is not yet well established, but studies show a decline in respiratory function and an increase in mortality associated with chronic colonisation, making it possible to classify the Achromobacter genus as an emerging pathogen in cystic fibrosis. It is possible that certain species or clones are more virulent or resistant, requiring the adaptation of measures to prevent cross-transmission in the centres concerned. However, until now, the identification of Achromobacter species has involved the use of molecular biology techniques that are not routinely applicable in diagnostic laboratories, limiting studies and the collection of epidemiological data. Recently, a database using MALDI-TOF mass spectrometry has been built for rapid and accurate species identification. In view of the local epidemiology and the current lack of data, it would be necessary and interesting to use this tool to study a cohort of cystic fibrosis patients in Réunion island (North and South sites) to see whether one species has a greater clinical impact than another (pathogenicity), and/or is more responsible for chronic colonisation.

Who May Be Eligible (Plain English)

Who May Qualify: - Minor or major cystic fibrosis patients - Patients with at least one sputum cytobacteriological test positive for Achromobacter spp. during the inclusion period. - Patients living in La Réunion island. - Patients for whom a non-opposition was obtained orally (if applicable from both one of the child's legal guardians and the child him/herself) Who Should NOT Join This Trial: - Patients without cystic fibrosis. - Patients with cystic fibrosis but no Achromobacter-positive ECBC during the study inclusion period Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Minor or major cystic fibrosis patients * Patients with at least one sputum cytobacteriological test positive for Achromobacter spp. during the inclusion period. * Patients living in La Réunion island. * Patients for whom a non-opposition was obtained orally (if applicable from both one of the child's legal guardians and the child him/herself) Exclusion Criteria: * Patients without cystic fibrosis. * Patients with cystic fibrosis but no Achromobacter-positive ECBC during the study inclusion period

Treatments Being Tested

OTHER

Biological analyses

A cytobacteriological examination of the sputum will be carried out and sent to the microbiology laboratory at the University Hospital of La Réunion. The micro-organisms will be quantified. The micro-organisms, and more specifically bacteria of the Achromobacter genus, will be identified by MALDI-TOF mass spectrometry using the published database (Garrigos et al.2021).

Locations (2)

CHU la Réunion North
Saint-Denis, Reunion
CHU la Réunion South
Saint-Pierre, Reunion